You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 金斯瑞生物科技(1548.HK)大漲超23% 券商稱公司細胞療法收穫在即
格隆匯 02-25 15:10
格隆匯2月25日丨金斯瑞生物科技(1548.HK)漲幅擴大至23.43%,報14.96港元創逾5個月新高,成交額放大至4.19億港元,總市值近300億港元。近日,公司發佈2020年業績預吿,全年預計虧損約2.70-3.06億美元。較2019年虧損1.18億美元有所擴大,主要是細胞療法業務繼續加大研發投入所致。興業證券指出,細胞療法收穫在即,非細胞療法業務穩步向上。公司細胞療法板塊的核心產品西達基奧侖賽已向美國FDA遞交該產品的上市申請,若進展順利有望於2021年下半年獲批。此外,公司生物製劑開發取得多項成績,仍有較大的成長空間;工業合成生物產品業務有望於2021年起進入盈利週期,逐步成長為公司第二個盈利點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account